{"id":"https://openalex.org/W2899558373","doi":"https://doi.org/10.1093/neuonc/noy148.083","title":"ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS","display_name":"ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS","publication_year":2018,"publication_date":"2018-11-01","ids":{"openalex":"https://openalex.org/W2899558373","doi":"https://doi.org/10.1093/neuonc/noy148.083","mag":"2899558373"},"language":"en","primary_location":{"id":"doi:10.1093/neuonc/noy148.083","doi":"https://doi.org/10.1093/neuonc/noy148.083","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noy148.083","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi23/26281283/noy148.083.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi23/26281283/noy148.083.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021656597","display_name":"Patrick Yung Wen","orcid":"https://orcid.org/0000-0002-0774-7700","observed_orcids":["https://orcid.org/0000-0002-0774-7700","https://orcid.org/0000-0003-3224-3042","https://orcid.org/0000-0002-2452-0540"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Wen","raw_affiliation_strings":["Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063511816","display_name":"Timothy Francis Cloughesy","orcid":"https://orcid.org/0000-0002-8656-7483","observed_orcids":["https://orcid.org/0000-0002-8656-7483"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy Cloughesy","raw_affiliation_strings":["UCLA Neuro-Oncology, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Neuro-Oncology, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055183757","display_name":"John de Groot","orcid":"https://orcid.org/0000-0003-1454-6461","observed_orcids":["https://orcid.org/0000-0003-1454-6461"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John de Groot","raw_affiliation_strings":["Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056817906","display_name":"James D. Battiste","orcid":"https://orcid.org/0009-0006-9537-7151","observed_orcids":["https://orcid.org/0009-0006-9537-7151"]},"institutions":[{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Battiste","raw_affiliation_strings":["University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA","institution_ids":["https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062059537","display_name":"James Stuart Garner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112583","display_name":"Kazia Therapeutics (Australia)","ror":"https://ror.org/029p5cv63","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210112583"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"James Garner","raw_affiliation_strings":["Kazia Therapeutics Limited, Sydney, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kazia Therapeutics Limited, Sydney, NSW, Australia","institution_ids":["https://openalex.org/I4210112583"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103874947","display_name":"Jeremy A. Simpson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112583","display_name":"Kazia Therapeutics (Australia)","ror":"https://ror.org/029p5cv63","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210112583"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jeremy Simpson","raw_affiliation_strings":["Kazia Therapeutics Limited, Sydney, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kazia Therapeutics Limited, Sydney, NSW, Australia","institution_ids":["https://openalex.org/I4210112583"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103885960","display_name":"Alan G. Olivero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Olivero","raw_affiliation_strings":["Genentech Inc, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech Inc, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082835319","display_name":"Elizabeth Robins Gerstner","orcid":"https://orcid.org/0000-0003-2382-3838","observed_orcids":["https://orcid.org/0000-0003-2382-3838"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Gerstner","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5132,"currency":"USD","value_usd":5132},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"20","issue":"suppl_6","first_page":"vi23","last_page":"vi23"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-mtor-inhibitors","display_name":"PI3K/mTOR inhibitors","score":0.8579999804496765},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9850000143051147},{"id":"https://openalex.org/keywords/newly-diagnosed-glioblastoma","display_name":"newly diagnosed glioblastoma","score":0.8949999809265137},{"id":"https://openalex.org/keywords/mgmt-promoter-methylation","display_name":"MGMT promoter methylation","score":0.7289999723434448},{"id":"https://openalex.org/keywords/blood-brain-barrier-penetration","display_name":"blood-brain barrier penetration","score":0.8149999976158142},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8489999771118164},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7300000190734863},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5770000219345093},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7149999737739563},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.37700000405311584},{"id":"https://openalex.org/keywords/brain-tumor-treatment","display_name":"brain tumor therapy","score":0.3109999895095825},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5519999861717224},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5040000081062317},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5932608842849731},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.565702497959137},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5514612197875977},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4905206561088562},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.48724403977394104},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4562893509864807},{"id":"https://openalex.org/C2777415128","wikidata":"https://www.wikidata.org/wiki/Q419849","display_name":"Fluorodeoxyglucose","level":3,"score":0.45585641264915466},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4514642059803009},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4453224539756775},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40715959668159485},{"id":"https://openalex.org/C2775842073","wikidata":"https://www.wikidata.org/wiki/Q208376","display_name":"Positron emission tomography","level":2,"score":0.30782803893089294},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.27711597084999084},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.21762609481811523},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1595417857170105},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.14103952050209045},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1093/neuonc/noy148.083","doi":"https://doi.org/10.1093/neuonc/noy148.083","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noy148.083","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi23/26281283/noy148.083.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5785873","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6216419","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6216419","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6216419","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro Oncol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/neuonc/noy148.083","doi":"https://doi.org/10.1093/neuonc/noy148.083","is_oa":true,"landing_page_url":"https://doi.org/10.1093/neuonc/noy148.083","pdf_url":"https://academic.oup.com/neuro-oncology/article-pdf/20/suppl_6/vi23/26281283/noy148.083.pdf","source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2899558373.pdf","grobid_xml":"https://content.openalex.org/works/W2899558373.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4251526733","https://openalex.org/W2985046962","https://openalex.org/W2511466478","https://openalex.org/W2999607433","https://openalex.org/W2519363128","https://openalex.org/W2560374365","https://openalex.org/W2287443485","https://openalex.org/W3083007608","https://openalex.org/W3112082321","https://openalex.org/W3110893794"],"abstract_inverted_index":{"GDC-0084":[0,31,51,95,140,281],"is":[1],"a":[2,39,60,145,181,225],"potent,":[3],"oral,":[4],"selective":[5],"small":[6],"molecule":[7],"inhibitor":[8,93],"of":[9,17,27,44,162,189,206,220,247,280],"class":[10],"I":[11,91],"phosphoinositide":[12],"3-kinase":[13],"and":[14,37,99,102,160,203,238,293],"mammalian":[15],"target":[16],"rapamycin":[18],"(PI3K/mTOR)":[19],"efficacious":[20],"in":[21,47,59,74,105,130,165,209,256,295],"GBM":[22,213],"models":[23],"driven":[24],"by":[25],"activation":[26],"the":[28,33,88,142,149,158,198,221,233,248,266,283],"PI3K":[29],"pathway.":[30],"crosses":[32],"blood-brain":[34],"barrier":[35],"(BBB)":[36],"achieves":[38],"brain":[40],"/":[41],"plasma":[42],"ratio":[43],"approximately":[45],"1.0":[46],"three":[48,267],"animal":[49],"species.":[50],"was":[52,96,109],"given":[53],"as":[54,287],"once":[55,115],"daily":[56],"oral":[57],"dosing":[58],"phase":[61,153,185,273],"1":[62],"study":[63,155,194,222],"(Wen":[64],"et":[65],"al,":[66],"J":[67],"Clin":[68],"Oncol":[69],"34,":[70],"2016(15)":[71],"suppl.2012;":[72],"NCT01547546)":[73],"47":[75],"patients":[76,119,166,210],"with":[77,87,117,127,144,167,171,195,211,214],"recurrent":[78],"high-grade":[79],"gliomas.":[80],"The":[81,107,151,184,217,260,272],"adverse":[82],"events":[83],"were":[84],"generally":[85],"consistent":[86,126],"established":[89],"Class":[90],"PI3K/mTOR":[92],"class-effects.":[94],"rapidly":[97],"absorbed":[98],"demonstrated":[100],"linear-":[101],"dose-proportional":[103],"increases":[104],"exposure.":[106],"MTD":[108],"determined":[110],"to":[111,231],"be":[112,254,263],"45":[113],"mg":[114],"daily,":[116],"7/8":[118],"receiving":[120],"this":[121],"dose":[122,268],"having":[123],"drug":[124],"exposures":[125],"anti-tumor":[128],"activity":[129,205,279],"pre-clinical":[131],"models.":[132],"Fluorodeoxyglucose-positron":[133],"emission":[134],"tomography":[135],"(FDG-PET)":[136],"scans":[137],"suggested":[138],"that":[139],"crossed":[141],"BBB,":[143],"uniform":[146],"distribution":[147],"throughout":[148],"brain.":[150],"current":[152],"2":[154,274],"will":[156,223,253,262,276],"investigate":[157],"efficacy":[159],"safety":[161],"GDC":[163,207],"0084":[164,208],"newly":[168],"diagnosed":[169],"GBM,":[170],"unmethylated":[172,215],"O6-methylguanine-methyltransferase":[173],"(MGMT)":[174],"promoter":[175],"status.":[176],"This":[177],"protocol":[178],"(NCT03522298)":[179],"has":[180],"2-part":[182],"design.":[183],"1b":[186],"component":[187,275],"consists":[188],"an":[190,257],"open-label,":[191],"multicenter":[192],"dose-escalation":[193,218],"expansion":[196,258],"assess":[197],"safety,":[199],"tolerability,":[200],"RP2D,":[201],"PK":[202],"clinical":[204,278],"newly-diagnosed":[212],"MGMT.":[216],"portion":[219],"use":[224],"standard":[226],"\u201c3":[227],"+":[228],"3\u201d":[229],"design":[230],"determine":[232],"MTDs":[234,250],"for":[235],"QD,":[236],"QOD":[237],"3":[239],"days":[240,242],"on/4":[241],"off":[243],"schedules.":[244],"At":[245],"each":[246],"identified":[249],"10":[251],"subjects":[252],"recruited":[255],"cohort.":[259],"RP2D":[261,284],"selected":[264],"from":[265],"schedules":[269],"being":[270],"tested.":[271],"evaluate":[277],"at":[282],"vs":[285],"temozolomide":[286],"adjuvant":[288],"therapy":[289],"following":[290],"surgical":[291],"resection":[292],"chemoradiation":[294],"224":[296],"patients.":[297]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-11-16T00:00:00"}